15-Oct-2012 - EuropaBio

From Promise to Productivity: Smart Policy for Sustainable EU Growth Through Biobased Products and Industrial Biotechnology

EuropaBio warmly welcomes the European Commission’s new proposal on industrial policy for growth and economic recovery.  Launched by Vice President Tajani, following extensive consultation and analysis, the Communication builds on the work of the Lead Market Initiative (LMI) and highlights biobased product markets as one of six key priority action lines with the greatest potential for delivering new products and for increasing productivity.  In addition, markets for Key Enabling Technologies (KETs), including Industrial Biotech, are highlighted as another of the six priority action lines destined for greater uptake through member state technology policies and European Innovation Partnerships (EIPs).

Commenting on the Communication, Joanna Dupont-Inglis, Director for Industrial Biotech at EuropaBio said: “We are delighted to see not only priority action lines on markets for KETs but also for biobased products, reflecting the real potential of this sector. The alignment of the six priority actions with sectors for smart specialisation, defined for cohesion policy in the member states, is also an important aspect.”

The Communication highlights the key role of Public Private Partnerships (PPPs) for Europe as a way of strengthening competitiveness, laying the foundations for the reindustrialisation of the economy, eliminating bottlenecks and getting innovation to market faster across the EU.  The importance of proposals for a Sustainable Process Industry PPP (SPIRE) and for a Biobased Industries PPP are also emphasised.

Lars Hansen, Chair of EuropaBio’s Industrial Biotech Council and President of Novozymes Europe summed up “Industrial biotech has been clearly identified by this communication as one of Europe’s leading technologies poised to deliver smart and sustainable jobs and growth.  The good news is that the gap remaining between high tech research and innovative, commercial competitiveness can be bridged to deliver the kind of economic recovery we need to see and feel. Investments in biorefinery demonstration facilities, through initiatives such as SPIRE and BioBased Industries PPPs, are now of paramount importance in order to develop thriving biobased product markets. For that, we need collective commitment and timely implementation of the joined-up policy making outlined by today’s Communication.”

Facts, background information, dossiers
More about EuropaBio
  • News

    Exceptional level of biotechnology innovation in Europe means a tie for the Most Innovative EU Biotech SME 2012

    In an exciting twist, two companies have been announced as winners of EuropaBio’s Most Innovative Biotech SME Award 2012.  Commission Vice President Tajani who presented the award, during the event hosted by Dr. Kay Swinburne MEP at the European Parliament, named both Austrian healthcare bi ... more

    Why we must produce more food with less water

    The world is thirsty because we are hungry,” notes the United Nations on World Water Day.  The world’s population reached 7 billion in 2011, and it is predicted to rise to at least 9 billion by 2050. More people living on our planet will require a more efficient use of dwindling natural res ... more

    New EIP: Support for bioeconomy key to productive and sustainable agriculture

    The Commission’s new European Innovation Partnership (EIP) sets the focus on the Common Agricultural Policy’s Rural Development Pillar and on the bioeconomy for delivering productive and sustainable agriculture across Europe. “The world is set to change dramatically over the coming decades” ... more

  • Companies


    EuropaBio, the European association for bioindustries, has 35 corporate members and 23 national biotechnology associations representing some 1000 biotech companies in Europe more

  • Associations


    EuropaBio is the political voice of the biotechnology industry in Europe. Our association of bioindustries has some 85 corporate and 7 associate members operating worldwide, 5 Bioregions and 25 national biotechnology associations, representing 1800 small and medium sized biotech companies ... more